Creatv Bio and Neovia Oncology Announce Strategic Partnership to Study Multiple Drug Resistance in Solid Tumors
Creatv Bio and Neovia Oncology have formed a strategic partnership to study multiple drug resistance (MDR) in patients with advanced solid tumors. The collaboration aims to generate translational and biomarker data to enhance patient stratification and understand treatment responses better. Neovia’s lead drug candidate, NEV-801, is under evaluation for its potential across various advanced solid tumors, and Creatv’s liquid biopsy technologies will be integrated into the clinical development program to provide insights into treatment dynamics.
MONMOUTH JUNCTION, N.J., June 2, 2026 /PRNewswire/ — Creatv Bio, a Division of Creatv MicroTech, Inc. (“Creatv”), a liquid biopsy company focused on innovative diagnostics for cancer, and Neovia Oncology LLC, a Delaware based pharmaceutical company dedicated to developing novel oncology…
